ALK Abello
ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco
ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco
ALK (ALKB:DC / OMX: ALK B) today announced that the company’s president & CEO, Peter Halling, is scheduled to give a company presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, 15 January 2026, at 9.45 AM PST / 12.45 PM EST / 6.45 PM CET.
Representatives of the company will be available for meetings at the conference.
ALK-Abelló A/S
For further information, please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
Business Development: Rasmus Just, tel. +45 4171 8431
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. ALK manufactures and markets allergy immunotherapy (‘AIT’) treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Wolters Kluwer N.V.9.1.2026 20:38:32 CET | Press release
Wolters Kluwer acquires StandardFusion
AACSB International9.1.2026 20:36:10 CET | Press release
AACSB Opens Public Comment on 2026 Global Standards for Business Education
Aspo Plc9.1.2026 17:30:00 CET | Press release
Aspo Plc: Share repurchase 9.1.2026
Aalborg Boldspilklub A/S9.1.2026 16:48:49 CET | Pressemeddelelse
Foreslået ændring i bestyrelsen i AaB A/S
Novartis Pharma AG9.1.2026 16:30:00 CET | Press release
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom